Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 study of BMS-986340 alone and with nivolumab or docetaxel in advanced solid tumors
jRCT2031240229Phase 2Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label trial of imzokitug in gastric or gastroesophageal junction adenocarcinoma, colorectal cancer (CRC), non-small cell lung cancer (NSCLC) and 7 more (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: adverse events, serious adverse events and 1 more. Started Jul 2024; status: active, not recruiting.
02
Drugs
imzokitug
03
Conditions
gastric or gastroesophageal junction adenocarcinomacolorectal cancer (CRC)non-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on jRCT2031240229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240229.